Source: Okayama University (JAPAN), Public Relations and Information Strategy
For immediate release: 29 November 2016
Okayama University research: Prevention of RNA virus replication
(Okayama, 29 November) Researchers at Okayama University have successfully cleaved influenza viral RNA to prevent its replication using novel artificial RNA restriction enzymes in laboratory cell cultures. While further improvements are needed, the findings show great promise and could lead to anti-viral drug development in future.
Developing technologies that can inactivate viruses and prevent them from infecting humans could transform the way in which we tackle various diseases. Several methods aiming at inactivating viruses have been tried, including preventing the binding of viral proteins and using artificial enzymes to ‘cleave’, or split, molecules in viral genomes.
By splitting a chosen molecular strand, such as DNA or RNA, essential bonds are broken and the molecule can no longer function correctly. In the case of viruses, integrating DNA or RNA cleaving ability into anti-viral drugs could prevent viral replication and infection within a host. Following recent success cleaving DNA in the human papillomavirus, Takashi Sera and co-workers at Okayama University have now used the same technique to cleave RNA in influenza cell cultures.
Firstly, the team developed artificial RNA restriction enzymes. These enzymes incorporate an artificial RNA binding protein, whose job is to target the correct virus, and an RNA cleaving enzyme that targets a specific domain in the viral RNA in order to create the split. Enzymes created for previous studies targeted the viral PIN domain but with limited success, and so Sera’s team created new RNA restriction enzymes targeting the staphylococcal nuclease (SNase) domain instead.
The researchers compared the ability of the SNase-based enzymes to cleave influenza RNA with PIN-fusion enzymes. They found that the SNase enzymes recognized and completely cleaved their target RNA in five minutes in cultures in the lab; in fact, the SNase enzymes had higher cleavage rates in one minute than the PIN-fusion enzymes had in two hours.
With improvements to the enzymes for use in animal (and eventually human) cells, the SNase restriction enzyme technique could one day prove to be a very powerful tool in the development of anti-viral drugs.
DNA and RNA viruses
Viruses have either DNA or RNA as their genomes. Examples of DNA viruses include herpes, chickenpox and smallpox – they replicate in nuclei after infiltrating host cells. RNA viruses, on the other hand, inject their RNA into host cell cytoplasm where it is then used to synthesize proteins and form replica viruses. RNA viruses include influenza, HIV and Ebola, to name but a few.
Scientists are keen to find ways of preventing both DNA and RNA viral infection and replication inside the body. Such technology could transform the way in which we tackle various diseases. One feasible way of stopping viral replication is to target the genetic machinery involved in the process – namely by cleaving, or splitting, the DNA or RNA strands so that they can no longer function correctly.
The techniques developed by Takashi Sera and his team at Okayama University involves the creation of artificial restriction enzymes – carefully-designed molecules incorporating proteins and enzymes that can home in on, and cleave, specific RNA or DNA targets. Their previous studies have been successful in cleaving DNA in human papillomavirus, and now they have used the same technique to cleave RNA in influenza cell cultures.
Implications of the current study
Following further work on the RNA restriction enzymes to ensure they are effective and safe for use in animal (and eventually human) cells, the team hope that their technique could lead to future development of anti-viral drug. Their findings represent a significant step forward in realising this goal.
Tomoaki Mori, Kento Nakamura, Keisuke Masaoka, Yusuke Fujita, Ryosuke Morisada, Koichi Mori, Takamasa Tobimatsu, Takashi Sera. Cleavage of influenza RNA by using a human PUF-based artificial RNA-binding protein–staphylococcal nuclease hybrid. Biochemical and Biophysical Research Communications, Volume 479, Issue 4, 28 October 2016, Pages 736-740.
Reference (Okayama Univ. e-Bulletin): Professor Sera's team
- Designer DNA-binding proteins to combat viral infections in agriculture and medicine. (2016)
- Immunizing plants: Creation of virus-resistant plants with artificial DNA-binding proteins. (2016)
- Okayama University at the Licensing Executives Society 2015 Annual Meeting in New York City. (2015)
- Selection as a Center for Excellence. (2014)
Professor Takashi Sera, Ph.D.
Department of Applied Chemistry and Biotechnology, Graduate
School of Natural Science and Technology, Okayama University,
3-1-1 Tsushimanaka, Kita-ku, Okayama 700-8530, Japan
e-mail : sera (a) cc.okayama-u.ac.jp
For inquiries, please contact us by replacing (a) with the @ mark.
1-1-1 Tsushima-naka , Kita-ku , Okayama 700-8530, Japan
Public Relations and Information Strategy
E-mail: www-adm (a) adm.okayama-u.ac.jp
For inquiries, please contact us by replacing (a) with the @ mark.
Okayama Univ. e-Bulletin: //www.okayama-u.ac.jp/user/kouhou/ebulletin/
Okayama Univ. e-Bulletin (PDF Issues): //www.okayama-u.ac.jp/user/kouhou/ebulletin/
About Okayama University (You Tube): https://www.youtube.com/watch?v=iDL1coqPRYI
Okayama University Image Movie (You Tube): https://www.youtube.com/watch?v=_WnbJVk2elA
Okayama University Medical Research Updates （OU-MRU）
Vol.1：Innovative non-invasive ‘liquid biopsy’ method to capture circulating tumor cells from blood samples for genetic testingVol.2：Ensuring a cool recovery from cardiac arrestVol.3：Organ regeneration research leaps forwardVol.4：Cardiac mechanosensitive integratorVol.5：Cell injections get to the heart of congenital defectsVol.6：Fourth key molecule identified in bone developmentVol.7：Anticancer virus solution provides an alternative to surgeryVol.8：Light-responsive dye stimulates sight in genetically blind patientsVol.9：Diabetes drug helps towards immunity against cancerVol.10：Enzyme-inhibitors treat drug-resistant epilepsyVol.11：Compound-protein combination shows promise for arthritis treatmentVol.12：Molecular features of the circadian clock system in fruit fliesVol.13：Peptide directs artificial tissue growthVol.14：Simplified boron compound may treat brain tumoursVol.15：Metamaterial absorbers for infrared inspection technologiesVol.16：Epigenetics research traces how crickets restore lost limbsVol.17：Cell research shows pathway for suppressing hepatitis B virusVol.18：Therapeutic protein targets liver diseaseVol.19：Study links signalling protein to osteoarthritisVol.20：Lack of enzyme promotes fatty liver disease in thin patientsVol.21：Combined gene transduction and light therapy targets gastric cancerVol.22：Medical supportive device for hemodialysis catheter punctureVol.23：Development of low cost oral inactivated vaccines for dysenteryVol.24：Sticky molecules to tackle obesity and diabetesVol.25：Self-administered aroma foot massage may reduce symptoms of anxietyVol.26：Protein for preventing heart failureVol.27：Keeping cells in shape to fight sepsisVol.28：Viral-based therapy for bone cancerVol.29：Photoreactive compound allows protein synthesis control with lightVol.30：Cancer stem cells’ role in tumor growth revealed